• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    5/6/24 8:06:38 AM ET
    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Monogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 13.99% to $1.14. The market value of their outstanding shares is at $2.2 million.
    • VYNE Therapeutics (NASDAQ:VYNE) shares increased by 13.74% to $2.98. The company's market cap stands at $42.0 million.
    • Allogene Therapeutics (NASDAQ:ALLO) stock increased by 13.02% to $3.47. The market value of their outstanding shares is at $592.4 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock rose 12.55% to $0.95.
    • Addex Therapeutics (NASDAQ:ADXN) shares increased by 12.4% to $10.06. The company's market cap stands at $10.7 million.

    Losers

    • GlycoMimetics (NASDAQ:GLYC) shares decreased by 78.7% to $0.39 during Monday's pre-market session. The market value of their outstanding shares is at $25.0 million.
    • Acutus Medical (NASDAQ:AFIB) shares fell 38.57% to $0.09. The market value of their outstanding shares is at $2.6 million.
    • EyePoint Pharmaceuticals (NASDAQ:EYPT) shares declined by 33.29% to $13.17. The market value of their outstanding shares is at $685.9 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares fell 16.47% to $0.34. The company's market cap stands at $1.2 million.
    • Ocular Therapeutix (NASDAQ:OCUL) shares declined by 15.08% to $5.24. The market value of their outstanding shares is at $810.7 million.
    • Predictive Oncology (NASDAQ:POAI) stock fell 13.82% to $1.56. The company's market cap stands at $6.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AFIB
    $ALLO
    $ALLR

    CompanyDatePrice TargetRatingAnalyst
    Allogene Therapeutics Inc.
    $ALLO
    1/9/2026$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Allogene Therapeutics Inc.
    $ALLO
    10/10/2025Neutral → Underweight
    Analyst
    Ocular Therapeutix Inc.
    $OCUL
    9/15/2025$21.00Buy
    Chardan Capital Markets
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    EyePoint Inc.
    $EYPT
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    Allogene Therapeutics Inc.
    $ALLO
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Ocular Therapeutix Inc.
    $OCUL
    4/8/2025Outperform
    William Blair
    More analyst ratings

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dugel Pravin sold $166,064 worth of shares (20,056 units at $8.28), decreasing direct ownership by 0.66% to 3,013,022 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:20:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $23,267 worth of shares (2,810 units at $8.28), decreasing direct ownership by 1% to 269,108 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:19:11 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Heier Jeffrey S. sold $25,312 worth of shares (3,057 units at $8.28), decreasing direct ownership by 0.94% to 323,368 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:18:30 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allogene upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    1/9/26 8:23:08 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allogene downgraded by Analyst

    Analyst downgraded Allogene from Neutral to Underweight

    10/10/25 8:22:32 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets initiated coverage on Ocular Therapeutix with a new price target

    Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00

    9/15/25 8:09:22 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

    2/25/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Announces Participation at Upcoming Investor Conferences

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: TD Cowen 46th Annual Health Care ConferenceForum: Fireside Chat Date: March 3, 2026Time: 2:30 p.m. ETBarclays 28th Annual Global Healthcare Conference 2026Forum: 1x1 Investor MeetingsDate: March 10, 2026Jefferies Biotech on the Beach SummitForum: 1x1 Investor MeetingsDate: March 11, 2026RBC Capital Markets Virtual Ophthalmology ConferenceForum: Fireside ChatDate: March 25, 2

    2/24/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ocular Therapeutix™ to Participate in March Investor Conferences

    BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference:Date: Monday, March 2, 2026Fireside Chat: 9:10 – 9:40 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Jefferies Biotech on the Beach Summit:Date: Tuesday, March 10, 2026Location: Miami, FL Citizens Life Sciences Conference 2026:Date: Wednesday, March 11, 2026Fireside Chat: 9:00 – 9:25 AM ETPresenter: Pravin U

    2/24/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    SEC Filings

    View All

    Ocular Therapeutix Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    2/27/26 4:02:39 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by VYNE Therapeutics Inc.

    10-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    2/27/26 8:01:39 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    2/20/26 4:08:43 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Michael Campbell as Chief Commercial Officer

    – Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of

    2/18/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

    Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company's new digital asset treasury strategy focused on the Aethir (ATH) token. The Company announced today that Shawn Matthews, CEO of

    10/14/25 8:00:00 AM ET
    $POAI
    Industrial Specialties
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Financials

    Live finance-specific insights

    View All

    EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/i8pzi8wg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A w

    2/25/26 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AFIB
    $ALLO
    $ALLR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care